The median time to achieve normocalcaemia was 4 days (range 2-14) for pamidronate and 3 days (range 2-6) with clodronate. The median duration of normnocalcaemia was 28 days (range 10-28 + days) after pamidronate and 14 days after clodronate (range 7-21 days) (P<0.01). Two patients who failed to respond to clodronate were successfully treated with pamidronate and achieved normocalcaemia for 14 and >28 days respectively. Two patients experienced fever after pamidronate but no significant toxicity was observed with either treatment. We conclude that both agents are effective in the management of hypercalcaemia of malignancy. At the doses studied. the effects of pamidronate are more complete and longer lasting than those of clodronate.
Hypercalcaemia is a common metabolic complication of malignancy and complicates the clinical course of 5-10% of patients with advanced cancers (Fisken et al., 1980) . Intravenous volume expansion to correct dehydration (Hosking et al., 1982) , coupled with bisphosphonate therapy to inhibit bone resorption has for some years been the treatment of choice (Ralston et al., 1985; Witte et al., 1987; Singer, 1990) . Despite the efficacy of treatment, recurrence of hypercalcaemia occurs unless effective treatment for the underlying cancer is possible. In many situations this cannot be achieved and the median survival for patients with hypercalcaemia of malignancy is less than 3 months (Ralston et al., 1985; Witte et al., 1987; Singer, 1990; O'Rourke et al., 1994) .
Three bisphosphonates are currently licensed for the treatment of hypercalcaemia of malignancy in the UK. They are etidronate (Didronel), clodronate (Bonefos, Loron) and pamidronate (Aredia). Both pamidronate and clodronate have been shown to be superior to treatment with etidronate which is the weakest inhibitor of bone resorption (Kanis et al., 1987; Ralston et al., 1989; Gucalp et al., 1992) . There has been only one previous randomised comparison of clodronate and pamidronate which showed a more complete and durable control of hypercalcaemia with pamidronate (Ralston et al., 1985) . However, the doses of both clodronate and pamidronate were lower than currently recommended. In this study we have performed a randomised comparison of the two agents at the maximum currently recommended dosages (Thiebaud et al., 1988; Nussbaum et al., 1993; O'Rourke et al., 1993) . The aim was to identify any difference in duration of normocalcaemia following treatment with clodronate or pamidronate.
Patients and methods
We studied 41 patients with hypercalcaemia of malignancy associated with various tumour types (Table I) Figure 1 shows the adjusted serum calcium for the two groups and Figure 2 the actuarial analysis for the duration of normocacaemia (n = 19 for pamidronate and n = 16 for clodronate). The number of patients observed at each time point is shown in Figure 2 Figures 3a and b show the serial changes in the fasting urinary excretion of calcium and hydroxyproin respectively. Urinary calcium decreased following treatment with both agents but rose again more rapidly following clodronate, with significant differences (P = <0.01) appearing between the two groups from 10 days. Changes in hydroxyproline were less marked but similar to the responses in urine calcium in that there was a significnt decrease in urinary hydroxyproline in both groups followed by an earler rebound in the clodronate-treated group. Figure 4 shows the serial changes in lymphocyte count. Consistent with advanced malignancy many patients had suppressd lymphocyte counts before treatment. There was a small but significnt dcrease (P = <0.05) in lymphocyte count during the first 7 days in the patients given pamidronate, but this was of no clinical signifi. There was no signifint change in haemoglobin, neutrophils or platelets. The only toxicity observed was fever during the first 24-48 h in three patients after administration of pamidronate, requiring treatment with paracetamol. Patients did not report any other side-effects of treatment. Serum creatinine rose in five patients treated with clodronate. Figure 5 shows (Figure 6b) . None of the patients in the pamidronate group showed primary resistance to treatment. Two patients were successfully retreated with pamidronate after recurrence of hypercalcaemia and one failed to respond to retreatment with either pamidronate or clodronate. All the other pamidronate treated patients (n = 16) went onto specific anti-cancer treatment and therefore were not assessable for response to retreatment. In the clodronate group, two of the four patients who failed to respond to clodronate were successfully treated with pamidronate with a duration of normocalcaemia of 14 and >28 days. The other two patients were considered too unwell to justify further intervention and died with their hypercalcaemia uncontrolled. Four patients were successfully retreated with clodronate after recurrence of hypercalcaemia and four failed to respond to retreatment. Again, all the other clodronate treated patients (n = 12) were given specific anti-cancer treatment and were not assessable for response to retreatment.
Both pamidronate and clodronate were effective in treating hypercalcaemia in this group of patients with advanced malignancy. The small difference in the response rate was not significant although it is of interest that two of three patients with hypercalcaemia resistant to clodronate did respond satisfactorily to pamidronate. Our study confirms the hypothesis that the duration of action of pamidronate is significantly longer than clodronate even when the latter is given at the maximum recommended dose (O'Rourke et al., 1993) . These results are consistent with those reported by Ralston et al. (1989) . In their study, the proportion of patients achieving normocalcaemia on day 6 was 14/16 (87.5%) with pamidronate and 6 16 (37.5%) with clodronate and the duration of normocalcaemia was median 29 (range 18-90) days (n = 6) for pamidronate and 12 (range 9-45) days (n = 7) for clodronate. The higher response rate in our study is attnrbutable to the higher doses used (Thiebaud et al., 1988; Body et al., 1987; Nussbaum et al., 1993) . The observed difference between the two bisphosphonates is due to the potency and different mechanism of action. Clodro- (Tyrell et al., 1994) . Further studies on the effect of clodronate on renal functions are under evaluation.
In the context of palliation of advanced malignancy. effects on symptoms and quality of life are of paramount importance. The bisphosphonates are known to be useful agents for the treatment of metastatic bone pain (Ernst et al., 1992; Purohit et al.. 1994; . In this study pain improved with both pamidronate and clodronate. although only in the pamidronate-treated group did this reach statistical significance. In this study we attempted to measure quality of life using the Rotterdam Symptom Checklist (RSCL) (De Haes et al.. 1990 ). Because of the poor medical state of many of these patients. data could only be collected on a proportion of the patients studied. However it was clear that control of hypercalcaemia resulted in a reduction in the RSCL score (improvement in quality of life). After 7 days the RSCL scores diverged as patients in the clodronate group began to experience recurrence of hypercalcaemia. These data support. in a more formal way. previous studies indicating that treatment of normocalcaemia is a useful palliative manoeuvre which improves quality of life in terminal cancer patients (Ralston et al.. 1990; Ernst et al.. 1992; Purohit et al.. 1994 ).
We conclude that both bisphosphonates are effective in the management of hypercalcaemia of malignancy. At the doses studied, the effects of pamidronate are more complete and longer lasting than those of clodronate.
